Cite

HARVARD Citation

    Modest, D. et al. (2017). FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?. European journal of cancer. pp. 71-73. [Online]. 
  
Back to record